GCVI Summit 2018
Skip Content

6 December 2017

Neon Therapeutics lights up $106m series B

Pharmstandard and Access Industries participated in a $36m extension to Neon’s series B round, which now stands at $106m.

Author: Sam McCaffrey, Reporter

Pharmaceutical company Pharmstandard International contributed to a $36m extension of a series B round for US-based immuno-oncology treatment developer Neon Therapeutics yesterday, bringing the total raised for the round to $106m.